Dr. Garon on the Efficacy of Datopotamab Deruxtecan in NSCLC


Edward B. Garon, MD, discusses the efficacy of datopotamab deruxtecan in patients with non–small cell lung cancer, as reported in the phase 1 TROPION-PanTumor01 trial.

Edward B. Garon, MD, professor of medicine, Division of Hematology/Oncology, Department of Medicine, Geffen School of Medicine at UCLA, discusses the efficacy of datopotamab deruxtecan (DS-1062a) in patients with non–small cell lung cancer (NSCLC), as reported in the phase 1 TROPION-PanTumor01 trial (NCT03401385).

TROPION-PanTumor01, data of which were presented during the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer, is a large study examining the agent in patients with other solid tumor cohorts in addition to NSCLC, according to Garon.

The study includes dose-expansion cohorts in which the agent is being administered at the following doses: 4 mg/kg (n = 50), 6 mg/kg (n = 50), and 8 mg/kg (n = 80). Notably, efficacy was observed at all dose levels in this heavily pretreated patient population, and was not limited to the highest dose of 8 mg/kg, Garon says.

Ultimately, the 8-mg/kg dose was associated with more toxicity, and the 6-mg/kg dose was chosen to be examined in further studies, Garon notes. Moreover, response rates experienced at the 6-mg/kg dose and 4-mg/kg doses were similar, at 28% and 24%, respectively, Garon concludes.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD